My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland

Abstract Background A global My Migraine Voice survey was conducted in 31 countries among 11,266 adults who suffered from ≥4 monthly migraine days (MMD). The aim of this retrospective observational survey-based study was to analyse the country specific results in Finland in order to understand the impact of migraine based on disease severity. Methods The included participants (3%, n = 338/11,266) were stratified by mean MMDs into 4 ≤ MMD < 8 (n = 133), 8 ≤ MMD < 15 (n = 139) and MMD ≥ 15 (n = 66) subgroups. Comorbidities, migraine-related emotional burden and impact on daily living and work productivity and activity impairment (WPAI) were assessed. Subgroup analysis on healthcare resource utilization (HCRU) due to migraine was assessed by visits to healthcare practitioners (HCPs) during the past 6 months and by hospitalizations and emergency room (ER) visits during the past 12 months. The group difference was tested using the one-way ANOVA and for categorical variables using the Chi-squared test. The association between HCRU and MMD and number of comorbidities was assessed using negative binomial regression analysis. Results Mean age was 44 years, 93% were women and 67% (n = 227) were employed. Chronic migraine (CM, MMD ≥ 15) was reported in 19.5% of the respondents. The negative impact on daily functioning and emotional burden increased significantly by migraine frequency. Mean number of comorbidities was 2.4, and mean number of HCP visits during the previous 6 months was 5.9. Increase in migraine frequency and comorbidities was associated with higher HCRU. Eighty-eight percent of the respondents reported negative impact on working life and 52% experienced overall work productivity impairment. Over previous month, the mean number of missed working days for all respondents was 2.8 days of which 54% were paid sick leave days, and in CM up to 6.0 days and 30%, respectively. Both absenteeism and presenteeism were higher in the CM group. Conclusions The emotional and functional burden was high, and the societal burden increased by frequency and severity of migraine, as shown by higher HCRU and reduced work productivity. There is a need to improve quality of care in migraine and improve migraine management related issues in both healthcare and society in Finland.

Download Full-text

Association of treatment satisfaction with healthcare resource utilization, quality of life and work productivity among patients with Inflammatory Bowel Disease currently using biologic treatment

Inflammatory Bowel Diseases ◽

10.1097/00054725-201112002-00100 ◽

2011 ◽

Vol 17 ◽

pp. S31-S32

Author(s):

J Vanderpoel ◽

JH Lofland ◽

M DiBonaventura ◽

Z Orlic

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Disease ◽

Resource Utilization ◽

Treatment Satisfaction ◽

Healthcare Resource ◽

Work Productivity ◽

Healthcare Resource Utilization ◽

Biologic Treatment ◽

Inflammatory Bowel

Download Full-text

Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2020-0092 ◽

2020 ◽

Vol 9 (12) ◽

pp. 891-902

Author(s):

Klaus Krueger ◽

Sven Remstedt ◽

Astrid Thiele ◽

Susanne Hohenberger

Keyword(s):

Resource Utilization ◽

Healthcare Resource ◽

Work Productivity ◽

Daily Practice ◽

Healthcare Resource Utilization ◽

Inflammatory Rheumatic Diseases ◽

Clinical Settings ◽

Activity Impairment ◽

Patient Reported

Aim: To analyze the quality of life (QoL), work productivity and activity impairment (WPAI) and healthcare resource utilization (HCRU) in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients receiving golimumab under routine clinical settings in Germany. Materials & methods: Prospective observational study, GO-ART, analyzed changes in WPAI, QoL and HCRU during 24 months of golimumab therapy. Results: Seven hundred and forty-eight patients (RA = 250, PsA = 249 and AS = 249) were enrolled. Substantial improvements in WPAI scores presenteeism, activity impairment and total work productivity impairment and QoL were observed at month three and were maintained through month 24. Fewer patients had disease-related hospitalizations and consulted physician at month 24 than at the baseline. Conclusion: Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, PsA and AS.

Download Full-text

Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis

Applied Health Economics and Health Policy ◽

10.1007/bf03261868 ◽

2012 ◽

Vol 10 (5) ◽

pp. 343-353 ◽

Cited By ~ 10

Author(s):

Ronald Vender ◽

Charles Lynde ◽

Vincent Ho ◽

Dina Chau ◽

Melanie Poulin-Costello

Keyword(s):

Resource Utilization ◽

Plaque Psoriasis ◽

Healthcare Resource ◽

Work Productivity ◽

Healthcare Resource Utilization ◽

Severe Plaque Psoriasis

Download Full-text

Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Sarcoma ◽

10.1155/2020/1765319 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Eric Nadler ◽

Kathleen Aguilar ◽

Chuck Wentworth ◽

Marley Boyd ◽

E. Susan Amirian ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Resource Utilization ◽

Clinical Characteristics ◽

Healthcare Resource ◽

Healthcare Resource Utilization ◽

Treatment Patterns ◽

Categorical Variables ◽

First Line ◽

Metastatic Soft Tissue Sarcoma

Introduction. This study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) and to examine treatment and healthcare resource utilization patterns of this patient population in a United States (US) community-based oncology practice setting over time. Methods and Materials. A retrospective observational study was conducted within the US Oncology Network (USON). Patients were eligible if they were diagnosed with advanced or metastatic STS and were treated at a USON site between 01 July 2015 and 31 August 2018. Demographic, clinical, and treatment characteristics were described for the overall study population. Comparisons between patients by time period (prior to and after October 2016) were evaluated using the T test for continuous variables and chi-squared test for categorical variables. Data were available for analysis through 31 August 2018. Results. Demographic and clinical characteristics of the eligible study cohort (N = 376) were similar between patients who initiated treatment before and after October 2016 (all p>0.05). Forty-three unique regimens were observed in the first-line setting, with the predominant regimen (gemcitabine + docetaxel) received by 33.2% (n = 125) patients. Prior to October 2016, 45.4% of patients received first-line gemcitabine + docetaxel, while 29.0% received this regimen after October 2016. Conclusions. While demographic and clinical characteristics were similar, treatment patterns changed in 2016. Future research should evaluate the impact of changing drug approvals and clinical trial results on future treatment patterns.

Download Full-text